Cyheptamide is anticonvulsant compound, developed by the Canadian company Ayerst Research Laboratories in the 1960s. Oral administration of compound at 14-25 mg/kg protected mice against the tonic phase of pentylenetetrazole convulsion and maximal electroshock seizure. Anticonvulsant activity of cyheptamide was confirmed in initial clinical studies, but the compound was not marketed.